Pharmacokinetic drug interactions among hematopoietic stem cell transplant recipients can result in either increases in serum concentrations of medications, which may lead to enhanced toxicity; or reduced serum concentrations, which can lead to treatment failure and the emergence of post transplant complications. The use of drugs that have a narrow therapeutic index, such as cyclosporine/tacrolimus (calcineurin inhibitors), increases the significance of these interactions when they occur. This report will review the clinical data evaluating the drug interactions of relevance to HSCT clinical practice, focusing on the pharmacokinetic interactions, and provides recommendations for managing these interactions to avoid both toxicity and treatment failure. Keywords: drug interactions; cytochrome P450; cyclosporine; tacrolimus; pharmacokinetic; CYP3A4; azoles A drug interaction is best defined as 'the possibility that one drug may alter the intensity of pharmacological effects of another drug that is given concurrently'. This results in either enhanced activity of the affected drug, which may lead to toxicity, or reduced activity of the affected drug, leading to therapeutic failure. It is also possible that there may be the appearance of a new effect that is not seen with either drug alone, for example, caspofungin and cyclosporine coadministration leading to elevated liver function tests. Drug interactions can be categorized as being either pharmacokinetic (PK) or pharmacodynamic in nature, and the remainder of this review will focus on PK interactions.
A drug interaction is best defined as 'the possibility that one drug may alter the intensity of pharmacological effects of another drug that is given concurrently'. This results in either enhanced activity of the affected drug, which may lead to toxicity, or reduced activity of the affected drug, leading to therapeutic failure. It is also possible that there may be the appearance of a new effect that is not seen with either drug alone, for example, caspofungin and cyclosporine coadministration leading to elevated liver function tests. Drug interactions can be categorized as being either pharmacokinetic (PK) or pharmacodynamic in nature, and the remainder of this review will focus on PK interactions.
Pharmacokinetic drug interactions -what are they?
Pharmacokinetic drug interactions influence the disposition of the drug in the body. When drugs are ingested, they undergo several processes to produce an end effect, including absorption, distribution, metabolism, and excretion. Interactions between two or more drugs may affect any of these phases, including the modulation of hepatic drug biotransformation, renal clearance, altered distribution, or changes in plasma protein binding. The most clinically relevant mechanisms of PK drug interactions relate to metabolism and elimination of drugs from the body, and involve the cytochrome P450 (CYP) enzymes and the transporter P-glycoprotein at the hepatic and intestinal levels, and glomerular filtration and tubular secretion at the renal level.
Cytochrome microsomal enzyme system
The CYP microsomal enzyme system is a family of hemoproteins that is responsible for the oxidative biotransformation of endogenous substrates and xenobiotics. CYPs are expressed in several tissues, with the main drug metabolizing CYPs concentrated in the liver, with lower expression in the lungs, kidneys, intestines, and brain. 1 Of the several different CYP isoforms identified, CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 have the greatest involvement in drug metabolism. An extensive list of drugs metabolized by the various isoenzymes is outlined in Table 1 . 2 The majority of oxidatively biotransformed drugs are metabolized, at least in part, by the CYP3A4 isoenzyme, which is responsible for drug metabolism both in the liver and the small intestine.
CYP-mediated drug interactions can occur by two separate mechanisms, namely enzyme inhibition and enzyme induction. Inhibition is the process whereby there is either enzyme inactivation or mutual competition of substrates at a catalytic site. The net response is inhibition of drug metabolism leading to increased serum concentrations, increased trough concentrations, and a prolongation of half-life. This causes potentiation of the pharmacodynamic effect, and often leads to enhanced toxicity, particularly among those agents with a very narrow therapeutic index, for example, cyclosporine and tacrolimus. Examples of substrates whose bioavailability is increased by inhibition include benzodiazepines (BZDs) (midazolam, triazolam), immunosuppressants (cyclosporine, tacrolimus, sirolimus), nonsedating antihistamines (astemizole, terfenadine), calcium channel blockers (amlodipine, diltiazem, nifedipine, verapamil), HMG CoAreductase inhibitors (atorvastatin, lovastatin, simvastatin), and many of the antineoplastic agents (etoposide, ifosfamide, cyclophosphamide, vinca alkaloids). Examples of inhibitors likely to be used in the hematopoietic stem cell transplant (HSCT) setting include the azole antifungals (fluconazole, itraconazole, ketoconazole, voriconazole), and the macrolide antibiotics (clarithromycin, erythromycin). Grapefruit juice, a commonly ingested 'health' drink, is also a potent inhibitor of CYP enzymes, and must be considered when reviewing drug interactions.
Induction is a process whereby there is increased synthesis or decreased degradation of CYP enzymes, resulting in decreased plasma levels of the substrate, and a decrease in its pharmacodynamic effects. Examples of enzyme inducers likely to be used in the HSCT population are rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, and St John's wort.
Drugs that require metabolism by the same CYP enzyme compete for binding to, and metabolism by CYP. 3 Therefore, in theory, any two drugs metabolized by identical CYP enzymes have a potential for interaction, although the clinical significance of the interaction will rely on the drug's relative affinities for binding to these enzymes, concentrations achieved in the endoplasmic reticulum after therapeutic doses, dependence on CYP for elimination, and therapeutic ratios. 
P-glycoprotein modulation and drug interactions
A second potential mechanism of PK drug interactions is thought to occur by the modulation of p-glycoprotein. P-glycoprotein, the product of the multidrug resistance gene (MDR1), is an ATP-dependent plasma membrane transporter. It is present on the proximal tubular cells of the kidneys, the bile cannalicular membrane of hepatocytes, endothelial cells of the blood-brain barrier and blood-testis barriers. P-glycoprotein is best known for its role in resistance of cancer cells to antineoplastic agents. Pglycoprotein also promotes the excretion of many other drugs, including digoxin, HIV protease inhibitors, and cyclosporine from the renal tubule and intestinal cells. 4 Administration of an agent that inhibits or induces Pglycoprotein activity can increase or decrease the clearance of P-glycoprotein substrates at the renal level, and increase or decrease bioavailability at the intestinal level. 4 
Drug-drug interactions that matter to transplanters
With the large number of pharmaceuticals available today, it is not surprising that drug interactions occur commonly, particularly in diseases that require polypharmacy. Due to the vast number of potential drug interactions that can occur in a given patient, only PK drug interactions of clinical relevance to the HSCT recipient will be discussed.
Immunosuppressants

Tacrolimus
Clinical trials in HSCT recipients have shown that targeted serum tacrolimus concentrations of between 10 and 20 ng/ml will minimize the risk of nephrotoxicity, while optimizing the prevention of GVHD. 5, 6 Awareness of agents that may alter serum concentrations of tacrolimus is therefore necessary to ensure that appropriate dose modifications are made to maintain therapeutic serum concentrations.
Tacrolimus is metabolized via the CYP3A4 isoenzyme system, both in the liver and in the small intestine.
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CYP3A4-mediated metabolism of tacrolimus is responsible for greater than 90% of its almost exclusively metabolic elimination. 8 Early research suggests that a drug interaction is clinically relevant when the metabolic fraction of a specific pathway, being inhibited, exceeds 50% of total clearance. 8 Based on this premise, inhibition or induction of CYP3A4 will lead to clinically significant PK drug interactions.
Many of the drug interactions with tacrolimus will be discussed separately in this review, under target drugs. Clinically significant drug interactions with tacrolimus are summarized in Table 2 , which also provides data on the strength of the interaction, the clinical effect, and the recommended management strategies.
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Cyclosporine Cyclosporine is similarly metabolized by the CYP3A4 isoenzyme system, and is therefore subject to many of the same interactions that occur with tacrolimus. Table 3 lists the clinically significant drug interactions with cyclosporine. Drug interactions with cyclosporine have been thoroughly investigated and even promoted, primarily among solid organ transplant programs. Cyclosporine is relatively expensive, and several drug interactions have reliably increased serum concentrations, enabling a reduction in dose and subsequent financial savings. This led to the concept of 'cyclosporine-sparing' therapy. The agent most commonly used is diltiazem, particularly as this may have a renoprotective effect and improve the graft itself following renal transplantation. The other agent evaluated for this purpose was ketoconazole, although it is not without its own toxicities, and is not the preferred agent.
There is one interaction that is specific to cyclosporine, as opposed to all calcineurin inhibitors. Coadministration of cyclosporine and sirolimus at the same time significantly increases the peak concentration and the area under the curve (AUC) of sirolimus. When these agents are separated by a period of 4 h, the magnitude of the interaction is reduced to within acceptable limits. In a PK study evaluating the potential PK interaction between tacrolimus and sirolimus, the same effect did not occur. 73 
Antifungal therapy
Azoles
When one agent within a class of drugs is reported to interact with a medication, a frequent assumption is that it is a 'class effect'. This assumption must not be made when considering clinically relevant drug interactions with azole antifungals. Drugs within the class have distinct differences, some with very different metabolic pathways. As a consequence, the presence of a drug interaction with one agent cannot be extrapolated to others within the class, nor can the magnitude of the interaction, as the azoles have different affinities for the CYP isoenzymes.
Fluconazole
Fluconazole is metabolized by CYP3A4 isoenzymes, and is also a potent inhibitor of CYP2C9 isoenzymes, leading to several potential drug interactions. The interaction of most concern in the allogeneic HSCT setting is that between fluconazole and the calcineurin inhibitors. Many centers have reported a clinically significant drug interaction between these agents, although the magnitude of the interaction is smaller than seen with itraconazole, ketoconazole, and voriconazole. Two issues warrant consideration: first, does the interaction occur when the agents are administered intravenously as well as orally, and second, does the interaction occur at all doses of fluconazole or is it a dose-dependent phenomenon?
Several case reports in the literature document a drug interaction between fluconazole and the calcineurin inhibitors, 10, [34] [35] [36] [37] [38] [39] [40] [41] although these are retrospective and uncontrolled observations. A controlled PK study of the interaction between intravenous cyclosporine/tacrolimus and intravenous fluconazole 400 mg daily in HSCT recipients demonstrated no statistically or clinically significant differences in steady-state concentration (C ss ) or clearance of tacrolimus, and a statistically but not clinically significant difference in the clearance of cyclosporine A. 9 These results did not support the experience seen with oral administration of both agents in many of the earlier case reports.
The answer to why this occurs lies in the distribution of CYP3A4 isoenzymes. CYP3A4 accounts for nearly 30% of the total P450 content in the human liver, and as much as 70% in the gut wall. 74 It has been postulated that the calcineurin inhibitors are also metabolized in the intestine by gut CYP3A4 isoenzymes. If this does occur, it would explain why a drug interaction is seen with fluconazole and tacrolimus/cyclosporine when administered orally, and not when administered intravenously. In addition to tacrolimus and cyclosporine being metabolized in this manner, there is also evidence that fluconazole inhibits CYP 3A4 substrate, which could result in increased serum tacrolimus or cyclosporine concentrations, with resultant toxicities. These differing observations lead to the conclusion that the interaction between tacrolimus/cyclosporine and fluconazole is due to the inhibition of gut metabolism of tacrolimus by fluconazole, resulting in increased absorption, AUC, and trough concentrations when these agents are administered orally. Therefore, appropriate dose reductions in cyclosporine and tacrolimus should be made when administered orally, but are unnecessary when given intravenously.
At the University of Florida HSCT program, we use lower doses of fluconazole (100 mg for autologous HSCT recipients; 200 mg for allogeneic HSCT recipients) as part of our antifungal prophylaxis strategy. When we concomitantly administer the calcineurin inhibitors with fluconazole at the lower oral daily dose, we do not note appreciable See Table 4 Monitor levels. k Tacrolimus dose Voriconazole 17 See Table 5 Monitor levels. 
a Drug interaction occurs when both agents administered orally and where fluconazole dose is 4200 mg/day. See Table 4 Monitor levels. k CyA dose Voriconazole 45 See Table 5 Monitor levels. increases in cyclosporine or tacrolimus serum concentrations. This suggests that the drug interaction is dosedependent, and that at doses of fluconazole of greater than 200 mg per day the interaction is much more likely to occur, requiring reductions in calcineurin inhibitor doses. 34, 36, 40 Fluconazole doses o200 mg daily typically do not require a dose adjustment of the calcineurin inhibitor. Other investigators have made similar observations. 34, 36, 38, 42 The other drugs with which fluconazole has been reported to interact include rifampin, phenytoin, and warfarin. Rifampin, a potent CYP3A4, CYP2C9, and CYP2C19 isoenzyme inducer, has been shown to significantly lower the AUC of fluconazole, increase clearance, and shorten the half-life of fluconazole when concomitantly prescribed. 75 This has led to treatment failures in Cryptococcal meningitis.
Phenytoin, a known potent inducer of CYP3A4 enzymes, is itself metabolized by CYP2C9 and CYP2C19. Fluconazole is a potent inhibitor of these isoenzymes, leading to increased serum concentrations of phenytoin, and clinical toxicity. Several case reports have indicated clinical phenytoin toxicity when phenytoin is administered with fluconazole at doses of 200 mg or greater per day. [76] [77] [78] [79] The onset of the interaction is relatively quick, within 2-6 days of concomitant administration. Phenytoin dosage should be reduced, and serum concentrations closely monitored. In patients receiving busulfan preparative regimens that utilize phenytoin prophylaxis, the start of fluconazole should be delayed until day zero.
Warfarin also requires close monitoring and potential dosage adjustment when prescribed with fluconazole. Fluconazole inhibits the metabolism of warfarin by CYP2C9, thus potentiating the hypoprothrombinemic response of warfarin, usually in the first few days of concomitant administration. Frequent monitoring of the INR should occur in this population. [80] [81] [82] [83] Itraconazole Like other members of the azole family, itraconazole undergoes extensive metabolism via the CYP3A4 enzyme system, and is subject to drug interactions with agents metabolized by a similar pathway. Itraconazole differs from fluconazole in that there is a relationship between drug dose, serum drug concentration, and efficacy. Serum concentrations of itraconazole greater than 500 ng/ml are required to prevent invasive fungal infection. 109 If enzyme inducers are coadministered, there is potential for increased metabolism of itraconazole, leading to reduced serum concentrations and potential drug failure. Drugs that decrease plasma concentrations of itraconazole include carbamazepine, 95, 96 phenobarbital, phenytoin, 105 isoniazid, rifampin, 106,107 and rifabutin 108 (see Table 4 ). Where possible, these should not be prescribed concomitantly with itraconazole, but, if no suitable alternative exists, routine drug monitoring of itraconazole levels is recommended to ensure that therapeutic levels are achieved (ie, 4500 ng/ml).
Itraconazole also has the ability to increase concentrations of many other medications (see Table 4 ). Those of most importance to HSCT recipients are cyclosporine, Case reports CYP3A4 induction
Nifedipine does not increase CyA levels and can be used safely.
b Ciprofloxacin [52] and levofloxacin [53] have been studied and no clinically significant interaction exists.
c PK of QND not known, thought to be due to CYP3A4 inhibition. 43, 44 These cases demonstrate that the addition of itraconazole to calcineurin inhibitor therapy increases the trough concentrations of the calcineurin inhibitors by two-to three-fold. In each of these case reports, additional factors could affect the outcome; so the frequency of occurrence and the magnitude of the drug interaction are not clear. Despite these uncertainties, the dose of cyclosporine and tacrolimus must be reduced, and based on available data the reduction should be at least 50% at the time that itraconazole is added to therapy. Evaluation of the pharmacokinetic drug interaction between intravenous itraconazole and intravenous calcineurin inhibitors has also been conducted. 11 Among allogeneic HSCT recipients, the mean steady-state trough concentration of cyclosporine and tacrolimus increased significantly. This was accompanied by a corresponding mean decrease in clearance. The increase in serum cyclosporine and tacrolimus concentrations is evident at the completion of the intravenous loading dose, when steady state is achieved. A 50% reduction in the dose of cyclosporine and tacrolimus should occur when starting intravenous itraconazole therapy.
The final class of drugs that requires consideration when prescribing itraconazole is the antineoplastic agents. There are numerous case reports in the literature, documenting greater neurotoxicity when itraconazole is prescribed during vinca alkaloid administration. [87] [88] [89] [90] [91] Cyclophosphamide, a common component of HSCT preparative regimens, is a prodrug that needs to undergo metabolism by CYP enzymes to produce the alkylator species required for its antineoplastic effect. The CYPs most involved in this process are CYP3A4 and CP2C9. 110 Coadministration of inhibitors of these isoenzymes may lead to increased exposure of cyclophosphamide, and increased toxicity. It has been suggested that concomitant administration of itraconazole with cyclophosphamide preparative regimens may lead to greater toxicity. Itraconazole has also been reported to reduce the clearance of busulfan when concomitantly prescribed with itraconazole. 111 Similarly, other antineoplastic agents that are metabolized by the CYP enzymes may have their serum concentrations enhanced, leading to greater toxicity. Metabolic pathways of the antineoplastic agent should be verified prior to coadministering with itraconazole. Patients receiving antineoplastic agents metabolized by the CYP3A4 isoenzyme system should have the itraconazole therapy held during the chemotherapy administration. Be mindful of the long half-life of itraconazole (64 h with oral dosing when at steady state), and stop the drug early enough to permit complete excretion of itraconazole and its metabolites.
Voriconazole
Voriconazole is similar to other members of the azole family in that it is subject to several drug interactions.
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Voriconazole, however, is metabolized by three separate CYP enzyme systems, namely CYP2C9, CYP2C19, and CYP3A4. This differs from the other azoles, which are metabolized primarily by CYP3A4. In vitro metabolism studies show that voriconazole is both a substrate and an inhibitor of these three enzymes. Due to extensive hepatic microsomal metabolism, caution is needed when prescribing voriconazole to transplant recipients. Prior to starting new medications, a screen of potential interactions should always be performed, and, if there are no data, evaluate the metabolic pathways of the new agent to evaluate the hypothetical risk of a drug interaction occurring.
Based on data from in vitro drug metabolism studies, voriconazole was subject to extensive clinical PK drug interaction studies prior to marketing. These studies were designed around target drugs that were likely to be coadministered to target patient populations and/or when an interaction might be expected on mechanistic grounds. The main clinically significant drug interactions that are known to occur when coprescribed with voriconazole are summarized in Table 5 and the effects of other drugs on voriconazole metabolism are summarized in Table 6 . There are several agents where coadministration with voriconazole is contraindicated, including sirolimus, ergot alkaloids, terfenadine, astemizole, cisapride, pimozide, quinidine, rifampin, and rifabutin. Coadministration of sirolimus with voriconazole results in such a significant increase in C max and AUC that dose reduction of sirolimus to a safe level is not possible. Rifampin, at the other extreme, induces the metabolism of voriconazole to such an extent that there is no dose of voriconazole that could be administered to a patient to overcome this inhibition. Of note, increasing the dose of voriconazole when coadministered with rifabutin can overcome the enzyme induction, although this approach should be avoided. The interaction with astemizole, cisapride, pimozide, quinidine, and ergot derivatives is due to potential prolongation of the QTc interval, leading to Torsades de pointes. A similar reaction is noted to occur when these agents are administered with several other members of the azole family (itraconazole, ketoconazole).
Again, the one therapeutic class of drugs where there is a lack of available information regarding drug interactions with voriconazole, is antineoplastic therapy. Several antineoplastic agents are metabolized by the CYP3A4 enzyme system. The ramifications of the potential drug interaction include elevated concentrations of the antineoplastic agent, leading to greater preparative regimen associated toxicity. Increased toxicity has been noted with itraconazole and antineoplastic therapy as discussed previously, and, more recently, the results of a PK study investigating the effect of CYP3A4 inhibition by ketoconazole on the pharmacokinetics of irinotecan were published. 119 Despite a 3.5-fold reduction in irinotecan dose when administered in combination with ketoconazole, the hematologic toxicities between the groups were similar. The coadministration of ketoconazole reduced the formation of inactive metabolites, and increased the exposure to the pharmacologically active metabolite. This clearly highlights the potential the azole antifungal agents have to increase concentrations of antineoplastic agents metabolized by CYP 3A4, leading to greater toxicity if dose reductions are not made. If a patient is receiving voriconazole for a preexisting fungal infection and is scheduled to undergo a HSCT, the best course of action would be to stop the voriconazole at least 30 h prior to the preparative regimen, and hold during the chemotherapy. Once the antineoplastic agent has been eliminated (approximately five half-lives of the antineoplastic agent), voriconazole can be restarted. Suitable other, nonazole antifungals can be instituted during the preparative regimen. Despite the numerous known drug interactions with voriconazole, if appropriate caution is used and modifications to target drugs are made, it is relatively safe to use voriconazole in the HSCT recipient.
Echinocandins
Caspofungin
Caspofungin, an echinocandin, is unique in that it is subject to few drug interactions. It is neither a substrate nor an inhibitor of the CYP enzyme system. PK studies demonstrate that caspofungin is not affected by the administration of itraconazole, 120 amphotericin B, 121 , or mycophenolate mofetil, 121 nor does it affect the pharmacokinetics of these target drugs. Caspofungin has been shown to decrease the peak plasma concentration, the 12-hour trough concentration and AUC of tacrolimus when these two agents are concomitantly administered, 122 and a corresponding increase in the dose of tacrolimus may be required. Close monitoring of tacrolimus concentrations should occur.
The interaction noted with tacrolimus is not a calcineurin inhibitor class effect, as a completely different interaction occurs between cyclosporine and caspofungin. Cyclosporine increases the AUC of caspofungin by 35%, whereas cyclosporine concentrations are unaffected by caspofungin. 121 In a healthy volunteer study, concomitant administration of cyclosporine and caspofungin resulted in elevations of liver function tests to 2-3 times the upper limit of normal. A follow-up study, using lower doses of caspofungin did not show the same magnitude of liver function test abnormalities. It could be postulated that the increased exposure of caspofungin leads to the hepatic abnormalities. Until this interaction is further characterized, concomitant administration of caspofungin with cyclosporine is not recommended unless the potential benefit outweighs the risks. Until further information is available, the alternative is to change cyclosporine to tacrolimus, as the interaction is not seen with this compound.
Micafungin
Micafungin differs from caspofungin in that it is not subject to the same drug interaction with cyclosporine. In the recently completed trial comparing fluconazole to micafungin in the prophylaxis of fungal infection in HSCT recipients, 123 approximately half of the 882 patients enrolled received concomitant micafungin and cyclosporine. No elevations in cyclosporine levels were seen. Similarly, no increases in liver function tests occurred over time. Based on these data, micafungin would be the preferred echinocandin in patients requiring concomitant cyclosporine, once final FDA approval is granted. m ¼ increase;
Drug interactions in the HCST recipient HL Leather
Benzodiazepines (BZDs)
Many of the BZDs are metabolized by the CYP3A4 isoenzymes, including midazolam, triazolam, and alprazolam. Diazepam is metabolized by CYP2C19 in addition to CYP3A4. If these agents are coadministered with an agent that is a potent inhibitor of CYP3A4, there will be an increase in serum concentrations of the BZD, potentially leading to increased sedation. 103, 104, 123 The azole antifungals pose the greatest risk, and prolonged monitoring should be performed in patient's receiving azoles and these BZDs. Lorazepam is commonly used in HSCT antiemetic protocols, primarily for its anxiolytic properties. It is eliminated by conjugation and therefore does not undergo a PK drug interaction with CYP3A4 modulators. Similarly, oxazepam and temazepam are safe to use in combination with CYP3A4 agents.
Opioid analgesics
During HSCT, many patients will develop severe mucositis, requiring narcotic analgesics for relief. Phenylpiperidine opiates, which include fentanyl, sufentanil, and alfentanil, are extensively metabolized by CYP3A4 isoenzymes. There is potential for elevated serum concentrations of these opioids if coadministered with medications that inhibit CYP3A4 isoenzymes (see Table 1 ). If coadministered, patients should be monitored more closely for excessive sedation and for low respiratory rates.
Antibacterials and antivirals
The majority of drug interactions with antibacterials and antivirals are pharmacodynamic in nature, that is, where coadministration of the antibacterial/antiviral with another agent affects the patient's response to the drug without affecting the PK.
Drug-food interactions
Several drug-food interactions have been reviewed extensively in the literature. 124 The interaction of most relevance to HSCT recipients is between grapefruit juice and medications used in the transplant setting. Grapefruit juice contains various flavonoids (eg, naringenin, naringin, quercertin, kaempferol) and nonfalvinoids that have been shown in vitro to affect the CYP enzyme system. The interaction is thought to occur following a reduction in CYP3A4 and CYP3A5 protein expression in enterocytes, with a resultant increase in drug bioavailability. This occurs in the small intestine, affecting those drugs administered via the oral route; however, ingestion of large quantities of concentrated grapefruit juice has the potential to also inhibit hepatic CYP3A4 microsomal enzymes. Grapefruit juice does not affect any other CYP enzymes in vivo. Some groups have postulated that grapefruit juice may also affect the P-glycoprotein transporter, although a recent PK study of grapefruit juice on the pharmacokinetics of digoxin, a sole P-glycoprotein substrate, demonstrated that grapefruit juice-mediated P-glycoprotein inhibition does not play a relevant role in drug interactions with grapefruit juice. 125 A grapefruit juice-drug interaction is most likely to occur with drugs that have a low bioavailability, due to extensive presystemic extraction, and who are substrates for CYP3A4. Owing to a wide variation among individuals in CYP3A4 expression, the interaction may not be seen uniformly across a population. Whether an interaction will occur in a patient is not readily predictable. Drugs that have their serum concentrations increased by coadministration with grapefruit juice are listed in Table 7 . [126] [127] [128] [129] [130] [131] [132] Patients should be advised to avoid taking medications on this list with grapefruit, unless advised to do so by their physician under controlled conditions.
The interaction of most interest to transplant physicians is between the calcineurin inhibitors and grapefruit juice. Although the data with cyclosporine [133] [134] [135] [136] [137] [138] are much more extensive, one may extrapolate that the same interaction occurs with tacrolimus. While the results with grapefruit juice and cyclosporine are variable, most studies have demonstrated increased exposure to cyclosporine, as well as an increase in cyclosporine trough concentrations. These PK changes occur with all formulations of cyclosporine.
In solid organ transplant recipients, the use of cyclosporine-sparing agents, such as diltiazem, erythromycin, and ketoconazole, have been extensively evaluated, primarily for their ability to reduce cyclosporine doses and reduce expenditure. [139] [140] [141] It is logical, therefore, to consider a 'natural' agent like grapefruit juice as a safe alternative; unfortunately, the interaction with grapefruit juice is unpredictable and variable, and should not be recommended as a means to routinely increase cyclosporine levels.
Drug-herb interactions
In a study of organ transplant recipients in 1997, 20% of the patients reported ingestion of herbal supplements, 142 and similar numbers of cancer patients have reported routine herbal supplement use. A major concern with herbal supplements is that patients do not perceive these as medication. When taking the history from the patient, these agents are often not reported, with up to 60% of patients not notifying physicians of consumption. 143 Therefore, a correlation of symptoms or changes in serum drug concentrations with the herbal product is difficult.
Reports of drug interactions with complementary and alternative medicines are increasing in the scientific literature. The most commonly affected pharmaceutical agents are warfarin and cyclosporine, although interactions with antineoplastics, antidepressants, antipsychotics, and oral contraceptives have been reported. The herbal medications most commonly reported to interact with prescription medications are garlic, gingko, ginseng, kava, and St John's wort (Hypericum perforatum).
The most important prescription medication-herbal medication interaction that applies to HSCT recipients is between the calcineurin inhibitors and St John's wort. St John's wort is a commonly used over-the-counter product for the treatment of depression and, understandably, is used by many HSCT patients. 144 Several case reports describing the interaction between cyclosporine and St John's wort in solid organ transplant recipients have been published. [66] [67] [68] [69] [70] [71] [72] The reports describe patients stabilized on cyclosporin undergoing significant reductions in the cyclosporine serum concentrations upon introduction of St John's wort. 68 The reductions in serum concentrations of cyclosporine were often associated with episodes of rejection. There is at least one case report characterizing a similar reaction between tacrolimus and St John's Wort. 33 St John's wort may reduce serum cyclosporine concentrations by enzyme induction of CYP3A4 hepatic microsomal enzymes, leading to faster metabolism of cyclosporine, or by increasing intestinal P-glycoprotein drug transporter expression. Increases in P-glycoprotein expression may have further implications when considering antineoplastic therapy and lack of response.
The interaction between cyclosporine and St John's wort may be difficult to identify if a good medication history is not taken. Since St John's wort is over-the-counter and classified as a 'complementary' or 'alternative' medication, patients are reticent to share their consumption with the medical team. Asking patients very specific questions about their herbal, vitamin, and over-the-counter drug use is very important. Mentioning common brand names may increase detection.
Most recently, St John's wort has been studied in combination with the antineoplastic irinotecan. 145 Concomitant administration of St John's wort with irinotecan lowered serum concentrations of the active metabolite of irinotecan (SN38), resulting in less myelosuppression. This has the potential to have a deleterious effect on treatment outcome. The interaction of St John's wort with other antineoplastic agents has not been evaluated, and until such time as there is information, concomitant administration of St John's wort in any form, including teas, with antineoplastic agents metabolized by CYP 3A4 should be avoided.
Conclusion
Drug interactions are common in the HSCT setting due to the number of medications and the complexity of the regimens. It is important that the medical teams caring for these patients are aware of these interactions, and screen all new medications against a full medication history to attempt to decrease the occurrence of an interaction. In addition to prescription medications, herbal supplements as well as the morning fruit juice have the potential to adversely affect HSCT patient outcomes.
With the availability of more new medications each year, it is clear that we must ensure that we understand the metabolic routes of these drugs, and in the absence of any substantive data, make out the 'best guess' as to the possibility of a potential drug interaction. Knowledge of the dominant CYPs involved in the metabolism of a drug makes it possible to anticipate from a list of inducers and inhibitors which drugs might cause significant interactions and reduce the risk to our patients. Table 7 Clinically relevant pharmacokinetic drug interactions with grapefruit juice 
